Return to homepagePandemic Pact

Investigation of an approved nebulised human Dornase enzyme (Pulmozyme) to reduce hyperinflammation in hospitalised people with COVID-19 (The COVASE study)

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    LifeArc

  • Principal Investigator

    N/A

  • Research Location

    United Kingdom

  • Lead Research Institution

    University College London, The Francis Crick Institute

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

University College London in collaboration with The Francis Crick Institute, with funding from LifeArc, is set to investigate an approved nebulised recombinant human deoxyribonuclease I (Dornase alfa) as a treatment for COVID-19. The COVASE trial aims to use Dornase alfa to reduce hyperinflammation in hospitalised participants with COVID-19.